Press Release
3/19/2026
For more information:
Rebecca Stauffer
AAPS Communications Manager
[email protected]
AAPS Announces Retirement of CEO Dr. Tina Morris
Arlington, VA—AAPS CEO Tina Morris, Ph.D., has announced that she will retire from her role effective April 3 and will continue to support the organization as a volunteer member.
A long-time AAPS member and respected scientist, Dr. Morris joined the association in early 2020 and quickly strengthened AAPS’ role as the convener of the pharmaceutical sciences. She elevated the organization’s scientific profile and reinforced its integrity during a period marked first by the Covid-19 pandemic and then by significant shifts in research funding across academia and industry.
“I’m honored to have led AAPS through a critical point in its history,” said Dr. Morris. “I look forward to continuing my support of the association’s scientific strategy as a volunteer member of the Scientific Advisory Committee. The future of AAPS is bright, particularly as we solidify our reputation as a convener of credible, cross‑sector science in pharmaceutical development.”
“Dr. Morris has transformed AAPS into a science-first association for pharmaceutical scientists across all specialties,” said Meena Subramanyam, Ph.D., 2026 AAPS President. “While I will miss working with her as CEO, I am grateful that she will continue to guide our scientific direction through the Scientific Advisory Committee. She has truly instilled a culture of scientific rigor and mission-driven planning within AAPS.”
Dr. Morris joined AAPS from the Parenteral Drug Association (PDA), where she served as Vice President of Scientific and Regulatory Affairs. Previously, she spent 15 years at the U.S. Pharmacopeia (USP), concluding her tenure as Senior Vice President of Compendial Sciences. She also held scientific roles at Human Genome Sciences, Inc. and Ciphergen Biosystems, Inc.
During her leadership, AAPS grew in membership engagement and scientific influence, maintaining its commitment to high-quality programming by transitioning its flagship meeting, PharmSci 360, online during the pandemic and later revitalizing the National Biotechnology Conference. She then focused AAPS’ resources on delivering cutting‑edge scientific content across in‑person events, digital platforms, and publications while strengthening the organization’s scientific strategy and volunteer infrastructure.
Dr. Morris also conceived and established the Chief Science Officer role—now open for applications—to guide AAPS’ scientific direction amid rapid technological advances in the pharmaceutical sciences. She will continue to support the hiring process for this position in Q2 2026.
American Association of Pharmaceutical Scientists (AAPS) is a 501(c)(3) non-profit association of more than 7,000 scientists and professionals employed in academia, industry, regulatory, and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and various events in person and online. www.aaps.org